STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α

Melanoma Research

Volumn 28, Issue 3, 2018, Pages 204-210

  Machiraju, Devayani ^a   Moll, Iris ^b,c   Gebhardt, Christoffer ^b   Sucker, Antje ^b,c   Buder Bakhaya, Kristina ^a   Schadendorf, Dirk ^b,c   Hassel, Jessica C ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

interferon; melanoma; signaling transduction activating transcription factor; therapy resistance

Indexed keywords

ALPHA INTERFERON; STAT3 PROTEIN; STAT5 PROTEIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL OUTCOME; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR CELL; BIOSYNTHESIS; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; SURVIVAL ANALYSIS; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT5 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 85046532565     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000435     Document Type: Article

References (40)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
2. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: Current status and future prospects. Oncologist 2011; 16:5-24.
3. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Natl Cancer Inst 2010; 102:493-501.
4. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 2002; 20:1818-1825.
5. Wheatley K, Ives N, Eggermont A, Kirkwood J, Cascinelli N, Markovic SN, et al. Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J Clin Oncol 2007; 25 (Suppl): 8526-8526.
6. Gajewski TF, Corrales L. New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev 2015; 26:175-178.
7. Ortiz A, Fuchs SY. Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine 2017; 89:4-11.
8. Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, et al. STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 2005; 15:1629-1639.
9. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 2006; 281:14111-14118.
10. Hassel JC, Winnemoller D, Schartl M, Wellbrock C. STAT5 contributes to antiapoptosis in melanoma. Melanoma Res 2008; 18:378-385.
11. Lo HW, Cao X, Zhu H, Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 2008; 14:6042-6054.
12. Lassmann S, Schuster I, Walch A, Gobel H, Jutting U, Makowiec F, et al. STAT3 mRNA and protein expression in colorectal cancer: Effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol 2007; 60:173-179.
13. Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, et al. STAT5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer 2010; 17:481-493.
14. Haddad BR, Gu L, Mirtti T, Dagvadorj A, Vogiatzi P, Hoang DT, et al. STAT5A/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol 2013; 182:2264-2275.
15. Cao S, Wang C, Zheng Q, Qiao Y, Xu K, Jiang T, et al. STAT5 regulates glioma cell invasion by pathways dependent and independent of STAT5 DNA binding. Neurosci Lett 2011; 487:228-233.
16. Sanchez-Ceja SG, Reyes-Maldonado E, Vazquez-Manriquez ME, Lopez-Luna JJ, Belmont A, Gutierrez-Castellanos S. Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer 2006; 54:163-168.
17. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, et al. Roles of activated Src and STAT3 signaling in melanoma tumor cell growth. Oncogene 2002; 21:7001-7010.
18. Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S, et al. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 2006; 126:2272-2280.
19. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, et al. Mcl-1, Bcl-XL and STAT3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007; 20:416-426.
20. Li H, Xiao W, Ma J, Zhang Y, Li R, Ye J, et al. Dual high expression of STAT3 and cyclinD1 is associated with poor prognosis after curative resection of esophageal squamous cell carcinoma. Int J Clin Exp Pathol 2014; 7:7989-7998.
21. Zhang S, Huang S, Deng C, Cao Y, Yang J, Chen G, et al. Co-ordinated overexpression of SIRT1 and STAT3 is associated with poor survival outcome in gastric cancer patients. Oncotarget 2017; 8:18848-18860.
22. Mao YL, Li ZW, Lou CJ, Pang D, Zhang YQ. Phospho-STAT5 expression is associated with poor prognosis of human colonic adenocarcinoma. Pathol Oncol Res 2011; 17:333-339.
23. Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, et al. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 2005; 11:5863-5868.
24. Mirtti T, Leiby BE, Abdulghani J, Aaltonen E, Pavela M, Mamtani A, et al. Nuclear STAT5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. Hum Pathol 2013; 44:310-319.
25. Huang C, Wang L, Yang X, Lai L, Chen D, Duan C. Expression of activated signal transducer and activator of transcription-3 as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma. World J Surg Oncol 2015; 13:314.
26. Morcinek JC, Weisser C, Geissinger E, Schartl M, Wellbrock C. Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase. Oncogene 2002; 21:1668-1678.
27. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 2007; 13:1523-1531.
28. Adamkova L, Souckova K, Kovarik J. Transcription protein STAT1: Biology and relation to cancer. Folia Biol (Praha) 2007; 53:1-6.
29. Davey HW, Wilkins RJ, Waxman DJ. STAT5 signaling in sexually dimorphic gene expression and growth patterns. Am J Hum Genet 1999; 65:959-965.
30. Clodfelter KH, Holloway MG, Hodor P, Park SH, Ray WJ, Waxman DJ. Sexdependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5bdependent activation of male genes and repression of female genes revealed by microarray analysis. Mol Endocrinol 2006; 20:1333-1351.
31. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 1997; 94:7239-7244.
32. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16:1103-1111.
33. Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, et al. STAT3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005; 174:3925-3931.
34. Kong H, Zhang Q, Zeng Y, Wang H, Wu M, Zheng T, et al. Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: A meta-analysis of literatures. Int. J Clin Exp Med 2015; 8:8525-8539.
35. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24:3164-3171.
36. Able AA, Burrell JA, Stephens JM. STAT5-interacting proteins: A synopsis of proteins that regulate STAT5 activity. Biology (Basel) 2017; 6:pii:E20.
37. Linke R, Pries R, Konnecke M, Bruchhage KL, Boscke R, Gebhard M, et al. Increased phosphorylation of STAT5b, but not STAT5a, in nasal polyps. Am J Rhinol Allergy 2015; 29:182-187.
38. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016; 375:819-829.
39. Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, et al. The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations. Genes Cancer 2012; 3:503-511.
40. Mohanty SK, Yagiz K, Pradhan D, Luthringer DJ, Amin MB, Alkan S, et al. STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. Oncotarget 2017; 8:85997-86010.